EGFR and non-small cell lung carcinoma: Erlotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment for advanced NSCLC patients with EGFR-sensitive mutations (19del or L858R) [3, 4].